Beida pharmaceutical's net profit in 2018 was 180 million yuan, 30% lower than the same period of last year
-
Last Update: 2019-01-23
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
[China Pharmaceutical network enterprise news] on January 22, Beida pharmaceutical recently released a performance forecast for 2018, with a net profit of up to 180 million yuan, down 30% from the same period last year According to the announcement, from January 1, 2018 to December 31, 2018, the net profit attributable to the shareholders of the listed company was 142 million yuan to 180 million yuan, a decrease of 45% - 30% over the same period of last year It is understood that during the reporting period, the company actively responded to changes in the market environment, organized a series of academic promotion activities, strengthened the implementation of hospital development and medical insurance policies, and Kemena's sales volume continued to maintain a high growth rate, with a year-on-year growth of 30.45%, and its operating revenue broke 1.2 billion yuan, with a year-on-year growth of about 19.05% During the reporting period, the company's innovation and development strategy showed results, and the R & D of new drug projects accelerated Among them, the application for listing and registration of the new generation of ALK inhibitor ensatinib hydrochloride was accepted, bpi-16350 was approved for clinical trials, bpi-23314, mrx2843 and bpi-17509 were accepted for clinical trials, vorolanib (CM082) and treprizumab injection (js001) were combined To obtain the notice of clinical trial During the reporting period, it is expected that the net profit attributable to the shareholders of the listed company will decrease year on year, mainly due to: with the accelerated development of new drug research and development, more investment in research and development; the implementation of the stock option incentive plan during the reporting period, the corresponding costs and expenses will increase; the amortization of intangible assets will increase year on year According to the data of digbeinet, Beida pharmaceutical is a high-tech enterprise founded by Dr returnees, with independent intellectual property rights innovation drug research and development as the core and integrating pharmaceutical research and development, production and marketing.
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.